Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

International Journal of Obesity

Volumn 40, Issue 11, 2016, Pages 1699-1706

  Svane, M S ^a,b   Jorgensen N B ^a,b   Bojsen Moller K N ^a,b   Dirksen, C ^a,b   Nielsen, S ^a   Kristiansen, V B ^a   Torang S ^b,c   Wewer Albrechtsen, N J ^b,c   Rehfeld, J F ^d   Hartmann, B ^b,c   Madsbad, S ^a,b   Holst, J J ^b,c  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Capital Region   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; DIPEPTIDYL PEPTIDASE IV; EXENDIN (9-39); GLICENTIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; OXYNTOMODULIN; PEPTIDE YY [3-36]; SITAGLIPTIN; UNCLASSIFIED DRUG; EXENDIN 9; PEPTIDE FRAGMENT; PEPTIDE YY;

ADULT; ARTICLE; CHOLECYSTOKININ BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIABETIC PATIENT; ENZYME INHIBITION; FEMALE; FOOD INTAKE; GASTRIC BYPASS SURGERY; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VISUAL ANALOG SCALE; ANTAGONISTS AND INHIBITORS; APPETITE; BLOOD; BODY WEIGHT LOSS; DENMARK; EATING; METABOLISM; MORBID OBESITY; PHYSIOLOGY; TREATMENT OUTCOME;

APPETITE; APPETITE REGULATION; CROSS-OVER STUDIES; DENMARK; DIABETES MELLITUS, TYPE 2; EATING; FEMALE; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; MALE; OBESITY, MORBID; PEPTIDE FRAGMENTS; PEPTIDE YY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84984607528     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2016.121     Document Type: Article

References (36)

1. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-Term cardiovascular events. JAMA 2012; 307: 56-65.
2. Odstrcil EA, Martinez JG, Santa Ana CA, Xue B, Schneider RE, Steffer KJ, et al. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr 2010; 92: 704-713.
3. Werling M, Fändriks L, Olbers T, Bueter M, Sjöström L, Lönroth H, et al. Roux-en-Y gastric bypass surgery increases respiratory quotient and energy expenditure during food intake. PLoS One 2015; 10: e0129784.
4. Schmidt JB, Pedersen SD, Gregersen NT, Vestergaard L, Nielsen MS, Ritz C, et al. Effects of RYGB on energy expenditure, appetite and glycemic control: a randomized controlled clinical trial. Int J Obes (Lond) 2016; 40: 281-290.
5. Dirksen C, Damgaard M, Bojsen-Møller KN, Jørgensen NB, Kielgast U, Jacobsen SH, et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone reponses after Roux-en-Y gastric bypass. Neurogastroenterol Motil 2013; 25: 346-e255.
6. Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and body weight after bariatric surgery. Lancet Diabetes Endocrinol 2014; 2: 152-164.
7. Bojsen-Møller KN, Dirksen C, Jørgensen NB, Jacobsen SH, Serup AK, Albers PH, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 2014; 63: 1725-1737.
8. Jørgensen NB, Jacobsen SH, Dirksen C, Bojsen-Møller KN, Naver L, Hvolris L, et al. Acute and long-Term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 2012; 303: E122-E131.
9. Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and betacell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012; 22: 1084-1096.
10. Wewer Albrechtsen NJ, Hornburg D, Albrechtsen R, Svendsen B, Toräng S, Jepsen SL, et al. Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. EBioMedicine 2016; 7: 112-120.
11. Le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780-785.
12. De Hollanda A, Casals G, Delgado S, Jiménez A, Viaplana J, Lacy AM, et al. Gastrointestinal hormones and weight loss maintenance following Roux-en-Y Gastric Bypass. J Clin Endocrinol Metab 2015; 100: 4677-4684.
13. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994; 35: S1-S4.
14. Batterham RL, Cowley Ma, Small CJ, Herzog H, Cohen Ma, Dakin CL, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
15. De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, et al. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011; 14: 700-706.
16. Verdic C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, et al. A metaanalysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389.
17. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120-5127.
18. Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW, et al. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab 2014; 306: E1248-E1256.
19. Keire DA, Mannon P, Kobayashi M, Walsh JH, Solomon TE, Reeve JR. Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am J Physiol Gastrointest Liver Physiol 2000; 279: G126-G131.
20. Jørgensen NB, Dirksen C, Bojsen-Møller KN, Jacobsen SH, Worm D, Hansen DL, et al. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013; 62: 3044-3052.
21. Svane MS, Bojsen-Møller KN, Nielsen S, Jørgensen NB, Dirksen C, Kristiansen VB, et al. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. Am J Physiol Endocrinol Metab 2016; 310: E505-E514.
22. Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem 1998; 44: 991-1001.
23. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535-539.
24. Wewer Albrechtsen NJ, Bak MJ, Hartmann B, Christensen LW, Kuhre RE, Deacon CF, et al. Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocr Connect 2015; 4: 50-57.
25. Toräng S, Bojsen-Moller KN, Svane MS, Hartmann B, Rosenkilde MM, Madsbad S, et al. In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans. Am J Physiol Regul Integr Comp Physiol 2016; 310: R866-R874.
26. Challis BG, Albrechtsen NJW, Bansiya V, Burling K, Barker P, Hartmann B, et al. Heterogeneity of glucagonomas due to differential processing of proglucagonderived peptides. Endocrinol Diabetes Metab Case Rep 2015; 2015: 150105.
27. Jørgensen NB, Dirksen C, Bojsen-Møller KN, Kristiansen VB, Wulff BS, Rainteau D, et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J Clin Endocrinol Metab 2015; 100: E396-E406.
28. Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Jacobsen SH, Clausen TR, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond) 2013; 37: 1452-1459.
29. Falkén Y, Hellström PM, Holst JJ, Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 2011; 96: 2227-2235.
30. Steinert RE, Schirra J, Meyer-Gerspach AC, Kienle P, Fischer H, Schulte F, et al. Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. Am J Clin Nutr 2014; 100: 514-523.
31. Melhorn SJ, Tyagi V, Smeraglio A, Roth CL, Schur EA. Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans. Appetite 2014; 82: 85-90.
32. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999; 48: 86-93.
33. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314: 687-699.
34. Medeiros MD, Turner AJ. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 1994; 134: 2088-2094.
35. Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2010; 12: 323-333.
36. Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 2013; 304: G1117-G1127.